To determine the role for mutations of MECP2 in Rett Syndrome, we generated isogenic 28 lines of human iPSCs (hiPSCs), neural progenitor cells (NPCs), and neurons from patient 29 fibroblasts with and without MECP2 expression in an attempt to recapitulate disease 30 phenotypes in vitro. Molecular profiling uncovered neuronal specific gene expression 31 changes including induction of a Senescence Associated Secretory Phenotype (SASP) 32 program. Patient derived Neurons made without MECP2 show signs of stress, including 33 induction of p53, and senescence. The induction of p53 appeared to affect dendritic 34 branching in Rett neurons, as p53 inhibition restored dendritic complexity. These 35 disease-in-a-dish data suggest that loss of MECP2 can lead to dendritic defects due to 36 an increase in aspects of neuronal aging. 37 38 39 40 41 42 43 44 45 46
Introduction
themselves did not seem to be affected by loss of MECP2 ( Fig 1E) . Dendritic complexity 136 has been shown extensively to be reliant on MECP2 expression in various models of Rett 137 Syndrome, and we found a statistically significant decrease in complexity in neurons 138 made in the absence of MECP2 by Sholl assay (Fig 1F) . In addition, we observed 139 qualitative differences in basic neuronal morphology between WT and mutant neurons, 140 where the neurons lacking MECP2 had shorter, thicker processes, and their soma was 141 not as well defined. 144 It has been suggested that loss of MECP2 only affects gene expression in neurons as 145 opposed to the hPSCs and NPCs from which they were derived 14 . We sought to 146 determine whether gene expression was affected in hiPSCs, NPCs or neurons in this 147 patient derived in vitro model. To optimize the search for molecular effects of loss of 148 MECP2 in hiPSCs, NPCs or neurons, we used defined neuronal cultures by following the 149 newly established 3i (three inhibitor) method to create populations of human interneurons 150 (Fig 2A) 34 . Interneurons are particularly relevant in the study of Rett Syndrome as 151 interneuron-specific deletion of Mecp2 in mice recapitulates many of the disease 152 symptoms 6, 8, 35, 36 . We validated the purity and quality of differentiation at each step by 153 immunostaining for markers typical of particular cell types (SOX2, SOX1 and NESTIN as 154 well as FOXG1 and NKX2.1 for NPCs; and Tuj1, MAP2 and GABA for interneurons) in 155 both WT and MUT cultures followed by quantification ( Fig S2A and B) . We first assessed 156 whether interneurons lacking MECP2 also showed diminished dendritic branching. In fact, in patient-derived interneurons made by 3i, defects in dendritic branching as 158 measured by the number of endpoints were clearly observed (Fig 2A) .
Loss of MECP2 affects the transcriptome of neurons
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We therefore proceeded with deep RNA seq (>120 million reads per sample) of hiPSC, 161 NPC and interneuron cultures. With such sequencing depth, it was possible to analyze 162 the RNA-seq reads for the known mutations present in the patients from which these lines 163 were made ( Fig S2C) . This analysis demonstrated that each line studied expressed 164 strictly either the WT or mutant allele of MECP2, and that XCI status was unchanged even 165 after extensive differentiation to neurons. We quantified the expression level of MECP2 in WT cells across these three stages of 169 development and found that the average RPKM was 3.1 for hiPSCs, 4.3 for NPCs, and 170 7.75 for interneuron cultures. This is consistent with consensus that MECP2 is enriched 171 in neuronal cells, but also demonstrates that it could potentially be relevant to hiPSC and 172 NPC physiology as well. However, high stringency analyses (FDR <0.05) of the RNA-173 seq data yielded very few gene expression changes due to loss of MECP2 in hiPSCs or 174 NPCs derived from Rett patients ( Fig 2B) , consistent with Li et al 14 . On the other hand, 175 interneuron cultures made from patient 982 showed many gene expression changes 176 when comparing two individual WT and MUT clones ( Fig 2B) . Gene ontology analysis 177 uncovered many neuronal physiology-related pathways were downregulated due to loss 178 of MECP2 in neurons, while genes associated with extracellular remodeling and cell 179 migration appeared to be induced ( Fig 2C) .
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Probing RNA-seq data, we also found that MECP2 null interneuron cultures showed a 182 strong increase in a group of genes that are known to be induced by senescent cells, 183 known as the Senescence Associate Secretory Program (SASP). The vast majority of 184 SASP genes that were changed in MECP2 null neurons were upregulated as opposed to 185 downregulated, suggesting a strong pattern of SASP induction ( Fig 2D) . The only 186 previous report linking MECP2 loss to senescence was performed by partial silencing of 187 this protein in mesenchymal stem cells, but the results were consistent with those shown 188 here for patient derived MECP2 null fibroblasts 37 . The induction of SASP was intriguing 189 in light of the fact that, while attempting to make clones of fibroblasts from patients with 190 Rett syndrome, we repeatedly found that clones lacking MECP2 did not expand well after To determine whether MECP2 null fibroblasts encounter senescence, we performed an 196 assay to detect endogenous beta-galactosidase, which is known to be a hallmark of this 197 process 38 . Indeed, MECP2 null fibroblasts showed strong activity in this senescence 198 assay ( Fig 3A) . We did not encounter such difficulties with clonal expansion once hiPSCs 199 or hiPSC-derived NPCs were made from patients, presumably because during 200 reprogramming, telomerase is strongly induced to restore telomere length at least beyond 201 the critical threshold 39-44 . In fact, our RNA-seq data showed that hiPSCs made from 202 patients had very high expression of TERT, and NPCs still expressed moderate levels, 203 while neurons did not express appreciable levels (average RPKM for TERT: hiPSC, 8.8; 204 NPC, 1.6; neuron, 0.006). Importantly, the same endogenous galactosidase activity 205 assay on interneurons showed a dramatic increase in senescence activity in neurons 206 lacking MECP2 ( Fig 3B) . These data indicate that loss of MECP2 leads to not only 207 induction of SASP, but also a bona fide senescence program in neurons. Interestingly, p53 induction due to telomere shortening was previously shown to cause 213 defects in dendritic branching 53, 54 , which is also the dominant phenotype in Rett 214 Syndrome. To begin to look for hallmarks of p53 induction in the absence of MECP2, we 215 performed RT-PCR for p53 related targets in cells with silencing of MECP2 by siRNA ( Fig   216   S3 ). This assay suggested that decreased MECP2 levels led to induction of p53 related 217 target genes such as p21, GADD45, DDIT4, and DDB2 ( Fig 3C) .
219
To determine the effect of loss of MECP2 in relation to cell stress pathways at the protein 220 level, we performed immunostaining for H2aX, PML, p53, and p21 in neurons with and 221 without MECP2. Staining for each of these markers showed strong increases in Syndrome 59-61 . Two independent studies showed that ICF patient-derived hiPSCs 276 displayed telomere shortening that was coupled to senescence of somatic derivatives 277 such as fibroblasts. ICF Syndrome only partially overlaps with Rett Syndrome in terms 278 of patient phenotypes, but is caused by mutations in DNMT3B, a de novo DNA 279 methyltransferase 62 . These findings together are highly relevant as DNMT3B is a key de 280 novo methyl transferase to create methylated DNA (5mC), which is the substrate for Tet 281 oxigenases to create 5-hydroxmethylated DNA (5hmC), which is known to be strongly 282 bound by MECP2 63 . Recently, another study showed that deletion of Tet enzymes, which 283 are critical to generate the 5hmC mark, led to shortened telomeres 64,65 . These studies 284 suggest that DNA hydroxymethylation could be important in the regulation of telomere 285 length. Because MECP2 is a methylated DNA-binding protein, it is tempting to speculate 286 that alterations of methylation lead to defective telomere maintenance. Regardless, it is tempting to speculate that treatments that could abrogate the p53 299 mediated stress response could potentially ameliorate patient outcomes. Pifithrin- has 300 already been shown to be an effective treatment to restore neuronal function in murine 301 models of injury or stroke 79-81 . Significant future effort will be devoted to determining both 302 whether telomere dysfunction is a common trigger for ID Syndromes. to data with two groups. ANOVA analyses were used for comparisons of data with greater 438 than two groups. A p value < 0.05 was considered as statistically significant. 
